Clinical trials: Temozolomide, completed
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Neuroendocrine Carcinoma
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
To study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as disease control rate (non-progressive disease)…
- Trial name
- NCT02248012
- Testing
- Everolimus , temozolomide
- Where
- Norway
- Volunteers
- 38 people
- Sponsor
- Haukeland University Hospital
Cancer, Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic radiation for newly diagnosed brain metastases.
- Trial name
- RAD0102 (NCT00582075)
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Glioblastoma
Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
This research study is exploring how the blood vessels in the participant's tumor change from treatment with bevacizumab, and how these changes affect the way their tumor absorbs temozolomide (TMZ).
- Trial name
- NCT01987830
- Testing
- MRI-PET, TMZ-PET
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Glioblastoma, Glioma
Radiomics for Prediction of Survival in GBM
Radiomics, the extraction of large amounts of quantitative image features to convert medical images into minable data, is an in-development field that intends to provide accurate risk stratification of oncologic patients.
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- Radiomics (NCT02666066)
- Where
- Netherlands
- Volunteers
- 289 people
- Sponsor
- Maastricht Radiation Oncology
Newly Diagnosed Glioblastoma Multiforme
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
The purpose of this study is to test the safety and effects of a combination of a study drug, Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug Temozolomide (chemotherapy agent) in patients…
- Trial name
- NCT01591577
- Testing
- Lapatinib/Temozolomide/radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pheochromocytoma, Metastatic, Paraganglioma, Malignant
The Efficacy and Safety of Temozolomide in Patients With MPPGL
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent.
- Conditions
- Pheochromocytoma, Metastatic, Paraganglioma, Malignant, Pheochromocytoma Malignant
- Trial name
- MPPGL (NCT05858177)
- Testing
- Temozolomide capsule
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking Union Medical College Hospital
Adult Glioblastoma, Depression
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
This clinical trial is studying magnetic resonance spectroscopy imaging in predicting response in patients to vorinostat and temozolomide in patients with recurrent, progressive, or newly diagnosed glioblastoma.
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Trial name
- NCT01342757
- Testing
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma.
- Trial name
- NCT01678352
- Testing
- Tumor Lysate Vaccine, Imiquimod
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Frank Lieberman
Glioma
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV).
- Trial name
- NCT00727506
- Testing
- BIBW 2992, TMZ, BIBW 2992 plus TMZ
- Where
- 28 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Stromal Tumors, Sdh
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib.
- Conditions
- Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
- Trial name
- NCT03556384
- Testing
- Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adam Burgoyne, MD, PhD
Brain Stem Glioma, Cerebral Astrocytoma
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
This randomized phase II/III trial is studying vorinostat, temozolomide, or bevacizumab to see how well they work compared with each other when given together with radiation therapy followed by bevacizumab and temozolomide in…
- Conditions
- Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma
- Trial name
- NCT01236560
- Testing
- Bevacizumab, Temozolomide, Vorinostat
- Where
- 132 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
This pilot early phase I trial studies the side effects of temozolomide, radiation therapy, and tumor treating fields therapy using Novo tumor treatment fields (TTF)-200A device in participants with glioblastoma.
- Trial name
- NCT03477110
- Testing
- Temozolomide, Radiation Therapy, NovoTTF-200A Device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Glioblastoma
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
Glioblastoma (GBM) accounts for approximately 50% of all glioma and among these tumors, are the most malignant. The cells of origin of glioma are still undefined, but the most putative target cells include astrocytes, neural stem…
- Trial name
- GLIOMELA (NCT02458508)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- University of Pisa
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
Sarcoma, Refractory Sarcoma
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
This is the first study to evaluate the safety and clinical activity of the combination of oral pazopanib, intravenous or oral irinotecan, and oral temozolomide in pediatric and young adult patients with relapsed or refractory…
- Trial name
- NCT03139331
- Testing
- Pazopanib, Irinotecan, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
Primary Objectives: 1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. 2.
- Trial name
- NCT00492141
- Testing
- Temozolomide, L9-NC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Carcinomas
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.
- Trial name
- TENEC (NCT04122911)
- Testing
- Temozolomide
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute, Naples